The Effect of Disintegrin-metalloproteinase ADAM9 in Gastric Cancer Progression

Overview

Journal Mol Cancer Ther

Date 2014 Oct 26

PMID 25344581

Citations 27

Authors

Jeong Min Kim

Hei-Cheul Jeung

Sun Young Rha

Eun Jeong Yu

Tae Soo Kim

You Keun Shin

Xianglan Zhang

Kyu Hyun Park

Seung Woo Park

Hyun Cheol Chung

Garth Powis

Affiliations

Soon will be listed here.

Abstract

Advanced gastric cancer is one of the most aggressive gastrointestinal malignancies, and ADAM (A disintegrin and metalloproteinase)-9 is a cell-surface membrane glycoprotein with oncogenic properties that is overexpressed in several cancers. Herein, we investigated the biologic mechanism of ADAM9 in the progression, proliferation, and invasion of gastric cancer. First, we detected ADAM's expression, processing, and protease activity in gastric cancer cells. Protease activity was moderately correlated with ADAM9 protein expression, but was better related to a processed smaller molecular weight (84 kDa) form of ADAM9. Knockdown of ADAM9 or specifically targeted monoclonal antibody (RAV-18) suppressed cancer cell proliferation and invasion in high ADAM9-expressing cells, not in low ADAM9-expressing cells. RAV-18 showed in vivo antitumor activity in a gastric cancer xenograft model. Hypoxia (1% oxygen) induced ADAM9 expression and functional activity in low ADAM9-expressing gastric cancer cells that was inhibited by siRNA knockdown or RAV-18 antibody to levels in normoxic cells. Overall, our studies show that ADAM9 plays an important role in gastric cancer proliferation and invasion, and that while expressed in some gastric cancer cells at high levels that are responsive to functional inhibition and antitumor activity of a catalytic site-directed antibody, other gastric cancer cells have low levels of expression and only when exposed to hypoxia do ADAM9 levels increase and the cells become responsive to ADAM9 antibody inhibition. Therefore, our findings suggest that ADAM9 could be an effective therapeutic target for advanced gastric cancer.

Citing Articles

NACC1 accelerates the progression of AML by regulating the ADAM9/PI3K/AKT axis.

Zhang Y, Zhong L, Wan P, Zhao Y, Wang M, Zhang H Int J Med Sci. 2025; 22(3):630-640.

PMID: 39898241 PMC: 11783076. DOI: 10.7150/ijms.102266.

A disintegrin and metallopeptidase domain (ADAM) 12, ADAM 17 mRNA and ADAM10 protein hold potential as biomarkers for detection of early gastric cancer.

Oh S, Lee S, Jin H, Choi S, Cha C, Lee J Sci Rep. 2025; 15(1):763.

PMID: 39755747 PMC: 11700123. DOI: 10.1038/s41598-024-84237-y.

Overexpression of a disintegrin and metalloproteinase 9 (ADAM9) in relation to poor prognosis of patients with oral squamous cell carcinoma.

Wu S, Cheng L, Luo T, Makeudom A, Wang L, Krisanaprakornkit S Discov Oncol. 2024; 15(1):582.

PMID: 39441449 PMC: 11499557. DOI: 10.1007/s12672-024-01422-1.

Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells, Which Enhances Transforming Growth Factor β1 Activation and Promotes Tissue Fibrosis in Patients With Lupus Nephritis.

Umeda M, Karino K, Satyam A, Yoshida N, Hisada R, Bhargava R Arthritis Rheumatol. 2024; 77(2):180-189.

PMID: 39279154 PMC: 11785507. DOI: 10.1002/art.42987.

Characteristics of lactate metabolism phenotype in hepatocellular carcinoma.

Zhang J, Dong K, Zhang X, Li C, Yu J, Wang W Sci Rep. 2023; 13(1):19674.

PMID: 37952028 PMC: 10640573. DOI: 10.1038/s41598-023-47065-0.

References

Alfa Cisse M, Gandreuil C, Hernandez J, Martinez J, Checler F, Vincent B . Design and characterization of a novel cellular prion-derived quenched fluorimetric substrate of alpha-secretase. Biochem Biophys Res Commun. 2006; 347(1):254-60. DOI: 10.1016/j.bbrc.2006.06.065. View

Roghani M, Becherer J, Moss M, Atherton R, Erdjument-Bromage H, Arribas J . Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J Biol Chem. 1999; 274(6):3531-40. DOI: 10.1074/jbc.274.6.3531. View

Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Rocken C . Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol. 2004; 131(1):41-8. DOI: 10.1007/s00432-004-0619-y. View

Shou Z, Jin X, Zhao Z . Upregulated expression of ADAM17 is a prognostic marker for patients with gastric cancer. Ann Surg. 2012; 256(6):1014-22. DOI: 10.1097/SLA.0b013e3182592f56. View

Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C . The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2004; 26(1):17-24. View

Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y . Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 2005; 312(3):331-9. DOI: 10.1016/j.yexcr.2005.10.032. View

Shigemura K, Sung S, Kubo H, Arnold R, Fujisawa M, Gotoh A . Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate. 2007; 67(7):722-31. DOI: 10.1002/pros.20565. View

Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I . ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer. 2004; 90(5):1053-8. PMC: 2409625. DOI: 10.1038/sj.bjc.6601645. View

Reiss K, Cornelsen I, Husmann M, Gimpl G, Bhakdi S . Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. J Biol Chem. 2011; 286(30):26931-42. PMC: 3143652. DOI: 10.1074/jbc.M111.243485. View

10.

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

11.

Fischer O, Hart S, Gschwind A, Prenzel N, Ullrich A . Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol. 2004; 24(12):5172-83. PMC: 419881. DOI: 10.1128/MCB.24.12.5172-5183.2004. View

12.

Sung S, Kubo H, Shigemura K, Arnold R, Logani S, Wang R . Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 2006; 66(19):9519-26. DOI: 10.1158/0008-5472.CAN-05-4375. View

13.

Miyazaki Y, Shinomura Y, Tsutsui S, Zushi S, Higashimoto Y, Kanayama S . Gastrin induces heparin-binding epidermal growth factor-like growth factor in rat gastric epithelial cells transfected with gastrin receptor. Gastroenterology. 1998; 116(1):78-89. DOI: 10.1016/s0016-5085(99)70231-3. View

14.

Schafer B, Gschwind A, Ullrich A . Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene. 2003; 23(4):991-9. DOI: 10.1038/sj.onc.1207278. View

15.

Becherer J, Blobel C . Biochemical properties and functions of membrane-anchored metalloprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 2003; 54:101-23. DOI: 10.1016/s0070-2153(03)54006-6. View

16.

Canault M, Leroyer A, Peiretti F, Leseche G, Tedgui A, Bonardo B . Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol. 2007; 171(5):1713-23. PMC: 2043531. DOI: 10.2353/ajpath.2007.070021. View

17.

Park J, Baek N, Lee S, Oh S, Jang S, Kim I . Preclinical efficacy testing for stomach and liver cancers. Cancer Res Treat. 2014; 46(2):186-93. PMC: 4022828. DOI: 10.4143/crt.2014.46.2.186. View

18.

Duffy M, Mullooly M, ODonovan N, Sukor S, Crown J, Pierce A . The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?. Clin Proteomics. 2011; 8(1):9. PMC: 3170276. DOI: 10.1186/1559-0275-8-9. View

19.

Barsoum I, Hamilton T, Li X, Cotechini T, Miles E, Siemens D . Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011; 71(24):7433-41. DOI: 10.1158/0008-5472.CAN-11-2104. View

20.

Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T . Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res. 2007; 27(2):793-9. View